Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab open-label extension in active psoriatic arthritis
2023-506528-95-00Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of treatment-emergent serious adverse events. Started Jul 2024; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2023-506528-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506528-95-00.